A Japanese family case with juvenile onset Behçet's disease caused by TNFAIP3 mutation

Allergology International

Volumn 66, Issue 1, 2017, Pages 146-148

  Ohnishi, Hidenori ^a   Kawamoto, Norio ^a   Seishima, Mariko ^a   Ohara, Osamu ^b   Fukao, Toshiyuki ^a  

^a GIFU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b KAZUSA DNA RESEARCH INSTITUTE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; COLCHICINE; HLA B ANTIGEN; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISOLONE; STEROID; TOCILIZUMAB; TUMOR NECROSIS FACTOR ALPHA INDUCED PROTEIN 3; TNFAIP3 PROTEIN, HUMAN;

APHTHOUS STOMATITIS; BEHCET DISEASE; BIOLOGICAL THERAPY; CASE REPORT; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DRUG DOSE REDUCTION; DRUG MEGADOSE; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FAMILY STUDY; FEMALE; GENE MUTATION; GENOTYPE; HAPLOINSUFFICIENCY; HAPLOTYPE; HEMATEMESIS; HETEROZYGOTE; HUMAN; IRIDOCYCLITIS; JAPANESE (PEOPLE); JUVENILE RHEUMATOID ARTHRITIS; LETTER; MAINTENANCE THERAPY; PHENOTYPE; POLYARTHRITIS; PRIORITY JOURNAL; PYREXIA IDIOPATHICA; REMISSION; SYNOVITIS; TREATMENT RESPONSE; ADULT; AGED; ASIAN CONTINENTAL ANCESTRY GROUP; BEHCET SYNDROME; CHILD; GENETICS; JAPAN; MALE; MUTATION; PATHOLOGY;

ADULT; AGED; ASIAN CONTINENTAL ANCESTRY GROUP; BEHCET SYNDROME; CHILD; FEMALE; HUMANS; JAPAN; MALE; MUTATION; TUMOR NECROSIS FACTOR ALPHA-INDUCED PROTEIN 3;

EID: 84978795818     PISSN: 13238930     EISSN: 14401592     Source Type: Journal    
DOI: 10.1016/j.alit.2016.06.006     Document Type: Letter

References (7)

1. 1 Sakane, T., Takeno, M., Suzuki, N., Inaba, G., Behcet's disease. N Engl J Med 341 (1999), 1284–1291.
2. 2 Zhou, Q., Wang, H., Schwartz, D.M., Stoffels, M., Park, Y.H., Zhang, Y., et al. Loss-of-function mutations in TNFAIP3 leading to A20 haploinsufficiency cause an early-onset autoinflammatory disease. Nat Genet 48 (2016), 67–73.
3. 3 Ma, A., Malynn, B.A., A20: linking a complex regulator of ubiquitylation to immunity and human disease. Nat Rev Immunol 12 (2012), 774–785.
4. 4 De, A., Dainichi, T., Rathinam, C.V., Ghosh, S., The deubiquitinase activity of A20 is dispensable for NF-kappaB signaling. EMBO Rep 15 (2014), 775–783.
5. 5 Kirino, Y., Zhou, Q., Ishigatsubo, Y., Mizuki, N., Tugal-Tutkun, I., Seyahi, E., et al. Targeted resequencing implicates the familial Mediterranean fever gene MEFV and the toll-like receptor 4 gene TLR4 in Behcet disease. Proc Natl Acad Sci U S A 110 (2013), 8134–8139.
6. 6 Hirano, T., Ohguro, N., Hohki, S., Hagihara, K., Shima, Y., Narazaki, M., et al. A case of Behcet's disease treated with a humanized anti-interleukin-6 receptor antibody, tocilizumab. Mod Rheumatol 22 (2012), 298–302.
7. 7 Vande Walle, L., Van Opdenbosch, N., Jacques, P., Fossoul, A., Verheugen, E., Vogel, P., et al. Negative regulation of the NLRP3 inflammasome by A20 protects against arthritis. Nature 512 (2014), 69–73.